Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product–receptor axis
Our present findings suggest that empagliflozin could ameliorate renal and metabolic derangements in type 2 diabetes animals by attenuating the AGE-RAGE axis.
Authors
- Ami Sotokawauchi (ORCID: https://orcid.org/0000-0002-4608-9341)
- Yoshinori Koga (ORCID: https://orcid.org/0000-0002-3419-8567)
- Takanori Matsui (ORCID: https://orcid.org/0000-0001-9506-7571)
- Sho-ichi Yamagishi
- Yuri Nishino
Institutions
- Kurume University (JP)
- SHOWA Medical University (JP)
- Fukui Prefectural University (JP)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1186/s10020-025-01138-0
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.36